{"transactions":[{"id":2766169,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":140748,"kind":"person","name":"OCAMPO CHRISTINE","position":1,"cik":"0001280154","reported_name":"OCAMPO CHRISTINE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PAO; CAO/Urovant Sciences,Inc."}}],"security":"Stock Option (Right to Buy)","published_at":"2021-03-31T12:30:24.000Z","date":"2021-03-29","kind":"disposition_to_issuer","acquired":false,"shares":70000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Upon consummation of the Merger, each option to purchase Common Shares that was outstanding and unexercised immediately prior to the effective time of the Merger, whether vested or unvested, and that had an exercise price per Common Share that is less than $16.25 was cancelled and automatically converted into the right to receive a cash amount for each Common Share that is subject to such option that is equal to the difference between $16.25 and the per share exercise price of such option, without interest and less any applicable withholding for taxes, as described in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":6.88,"expiration_date":"2029-01-06","underlying":"Common Shares","underlying_shares":70000},"source":{"system":"sec-edgar","filing":"0000899243-21-014102","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1280154/000089924321014102/doc4.xml","form_type":"4"}},{"id":2766168,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":140748,"kind":"person","name":"OCAMPO CHRISTINE","position":1,"cik":"0001280154","reported_name":"OCAMPO CHRISTINE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PAO; CAO/Urovant Sciences,Inc."}}],"security":"Stock Option (Right to Buy)","published_at":"2021-03-31T12:30:24.000Z","date":"2021-03-29","kind":"disposition_to_issuer","acquired":false,"shares":3750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Upon consummation of the Merger, each option to purchase Common Shares that was outstanding and unexercised immediately prior to the effective time of the Merger, whether vested or unvested, and that had an exercise price per Common Share that is less than $16.25 was cancelled and automatically converted into the right to receive a cash amount for each Common Share that is subject to such option that is equal to the difference between $16.25 and the per share exercise price of such option, without interest and less any applicable withholding for taxes, as described in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":13.65,"expiration_date":"2028-10-14","underlying":"Common Shares","underlying_shares":3750},"source":{"system":"sec-edgar","filing":"0000899243-21-014102","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1280154/000089924321014102/doc4.xml","form_type":"4"}},{"id":2766167,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":140748,"kind":"person","name":"OCAMPO CHRISTINE","position":1,"cik":"0001280154","reported_name":"OCAMPO CHRISTINE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PAO; CAO/Urovant Sciences,Inc."}}],"security":"Stock Option (Right to Buy)","published_at":"2021-03-31T12:30:24.000Z","date":"2021-03-29","kind":"disposition_to_issuer","acquired":false,"shares":133500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Upon consummation of the Merger, each option to purchase Common Shares that was outstanding and unexercised immediately prior to the effective time of the Merger, whether vested or unvested, and that had an exercise price per Common Share that is less than $16.25 was cancelled and automatically converted into the right to receive a cash amount for each Common Share that is subject to such option that is equal to the difference between $16.25 and the per share exercise price of such option, without interest and less any applicable withholding for taxes, as described in the Merger Agreement."}],"balance_after":0,"derivative":{"exercise_price":3.64,"expiration_date":"2027-11-19","underlying":"Common Shares","underlying_shares":133500},"source":{"system":"sec-edgar","filing":"0000899243-21-014102","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1280154/000089924321014102/doc4.xml","form_type":"4"}},{"id":2766166,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":140748,"kind":"person","name":"OCAMPO CHRISTINE","position":1,"cik":"0001280154","reported_name":"OCAMPO CHRISTINE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PAO; CAO/Urovant Sciences,Inc."}}],"security":"Common Shares","published_at":"2021-03-31T12:30:24.000Z","date":"2021-03-29","kind":"disposition_to_issuer","acquired":false,"shares":68971,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"Immediately prior to the consummation of the Merger, these securities were time-based restricted share units (\"RSUs\") subject to vesting and previously granted pursuant to the Issuer's 2017 Equity Incentive Plan.  Upon the consummation of the Merger, each RSU, whether vested or unvested, that had not been settled in Common Shares prior to the effective time of the Merger was canceled and converted automatically into the right to receive $16.25 per each such RSU, without interest and less any applicable withholding for taxes, as described in the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon the consummation of the Merger, each outstanding common share of the Issuer (\"Common Share\") was cancelled and converted into the right to receive $16.25 per share in cash, without interest and less any applicable withholding for taxes, as described in the Merger Agreement."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-21-014102","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1280154/000089924321014102/doc4.xml","form_type":"4"}},{"id":2766165,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":140748,"kind":"person","name":"OCAMPO CHRISTINE","position":1,"cik":"0001280154","reported_name":"OCAMPO CHRISTINE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PAO; CAO/Urovant Sciences,Inc."}}],"security":"Common Shares","published_at":"2021-03-31T12:30:24.000Z","date":"2021-03-29","kind":"disposition_to_issuer","acquired":false,"shares":9810,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon the consummation of the Merger, each outstanding common share of the Issuer (\"Common Share\") was cancelled and converted into the right to receive $16.25 per share in cash, without interest and less any applicable withholding for taxes, as described in the Merger Agreement."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-21-014102","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280154/000089924321014102/doc4.xml","form_type":"4"}},{"id":3163477,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":140748,"kind":"person","name":"OCAMPO CHRISTINE","position":1,"cik":"0001280154","reported_name":"OCAMPO CHRISTINE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PAO;CAO/Urovant Sciences, Inc"}}],"security":"Common Shares","published_at":"2020-05-04T16:53:53.000Z","date":"2020-05-01","kind":"grant","acquired":true,"shares":44346,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"25% of the Restricted Stock Units shall vest on May 1, 2021; the remaining Restricted Stock Units vest in 12 equal quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer through each such vesting date."}],"balance_after":77179,"source":{"system":"sec-edgar","filing":"0001209191-20-026839","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280154/000120919120026839/doc4.xml","form_type":"4"}},{"id":3314422,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":140748,"kind":"person","name":"OCAMPO CHRISTINE","position":1,"cik":"0001280154","reported_name":"OCAMPO CHRISTINE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PAO;CAO/Urovant Sciences, Inc"}}],"security":"Common Shares","published_at":"2020-01-09T16:32:05.000Z","date":"2020-01-07","kind":"grant","acquired":true,"shares":32833,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"25% of the Restricted Stock Units shall vest on January 7, 2021; the remaining Restricted Stock Units vest in 12 equal quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer through each such vesting date."}],"balance_after":32833,"source":{"system":"sec-edgar","filing":"0000899243-20-000882","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280154/000089924320000882/doc4.xml","form_type":"4"}},{"id":3700004,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":140748,"kind":"person","name":"OCAMPO CHRISTINE","position":1,"cik":"0001280154","reported_name":"OCAMPO CHRISTINE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PFAO;CAO/Urovant Sciences, Inc"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-01-08T17:22:32.000Z","date":"2019-01-06","kind":"grant","acquired":true,"shares":70000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the total shares underlying the option shall vest and become exercisable on January 2, 2020; the remaining shares vest in 12 equal quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer through each such vesting date."}],"balance_after":70000,"derivative":{"exercise_price":6.88,"expiration_date":"2029-01-06","underlying":"Common Shares","underlying_shares":70000},"source":{"system":"sec-edgar","filing":"0000899243-19-000776","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280154/000089924319000776/doc4.xml","form_type":"4"}},{"id":3788068,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":140748,"kind":"person","name":"OCAMPO CHRISTINE","position":1,"cik":"0001280154","reported_name":"OCAMPO CHRISTINE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PFAO;CAO/Urovant Sciences,Inc."}}],"security":"Stock Option (Right to Buy)","published_at":"2018-10-17T18:07:26.000Z","date":"2018-10-15","kind":"grant","acquired":true,"shares":3750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the total shares underlying the option shall vest and become exercisable on October 1, 2019; the remaining shares vest in 12 equal quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer through each such vesting date."}],"balance_after":3750,"derivative":{"exercise_price":13.65,"expiration_date":"2028-10-14","underlying":"Common Shares","underlying_shares":3750},"source":{"system":"sec-edgar","filing":"0001209191-18-055410","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280154/000120919118055410/doc4.xml","form_type":"4"}},{"id":4302864,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":140748,"kind":"person","name":"OCAMPO CHRISTINE","position":1,"cik":"0001280154","reported_name":"OCAMPO CHRISTINE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-05-26T20:05:32.000Z","date":"2017-05-24","kind":"grant","acquired":true,"shares":52500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase a total of 52,500 shares of the Issuer's Common Stock. 36,000 shares will vest ratably each month over three years beginning on May 24, 2017 (the \"grant date\"). 16,500 shares will vest on the later of achievement of a performance-related goal or the first anniversary of the grant date."}],"balance_after":52500,"derivative":{"exercise_price":5.5,"expiration_date":"2027-05-23","underlying":"Common Stock","underlying_shares":52500},"source":{"system":"sec-edgar","filing":"0000899243-17-014539","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404281/000089924317014539/doc4.xml","form_type":"4"}},{"id":4324527,"issuer":{"id":6160,"kind":"organization","name":"Eledon Pharmaceuticals, Inc."},"owners":[{"id":140748,"kind":"person","name":"OCAMPO CHRISTINE","position":1,"cik":"0001280154","reported_name":"OCAMPO CHRISTINE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2017-05-12T00:30:39.000Z","date":"2017-05-10","kind":"purchase","acquired":true,"shares":10010,"price":9.99,"value":99999.9,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"All numbers give effect to the 1:9 reverse stock split effected by the Company on May 11, 2017."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"All numbers give effect to the 1:9 reverse stock split effected by the Company on May 11, 2017."}],"balance_after":21590,"source":{"system":"sec-edgar","filing":"0000899243-17-012930","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1404281/000089924317012930/doc4.xml","form_type":"4"}}]}